Log In
Print
BCIQ
Print
Print this Print this
 

ALKS 3831

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionCombination of samidorphan, a mu opioid receptor (OPRM1; MOR) antagonist, and olanzapine, an antipsychotic monoaminergic receptor antagonist
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia; Treat schizophrenia co-occuring with alcohol use disorder
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today